| Literature DB >> 35648314 |
Clara Gasparri1, Simone Perna2, Gabriella Peroni3, Antonella Riva4, Giovanna Petrangolini4, Milena Anna Faliva3, Maurizio Naso3, Mariangela Rondanelli5,6.
Abstract
PURPOSE: Obesity is a chronic disease characterized by a complex variable clinical presentation with comorbidities. A multidisciplinary residential program (MRP) represents one of the best options for treating obesity. The purpose of this study was to evaluate the effectiveness of 8-week MRP on weight loss, body composition assessed by DXA, and metabolic blood parameters between entry (T0) and discharge (T1). The secondary endpoint was the evaluation of the patients' adherence to diet during the check-up outpatient visits, at 2 (T2), 6 (T3), and 12 (T4) months after discharge.Entities:
Keywords: Body composition; Hospitalization; Multidisciplinary residential program; Obesity
Mesh:
Substances:
Year: 2022 PMID: 35648314 PMCID: PMC9556418 DOI: 10.1007/s40519-022-01412-8
Source DB: PubMed Journal: Eat Weight Disord ISSN: 1124-4909 Impact factor: 3.008
Anthropometric characteristics at baseline
| Variable | Mean value ± ds |
|---|---|
| Subjects | |
| Age (years) | |
| Total | 58.48 ± 13.97 |
| Male | 55.08 ± 14.97 |
| Female | 61.78 ± 12.89 |
| Height (m) | |
| Total | 1.60 ± 0.11 |
| Male | 1.70 ± 0.07 |
| Female | 1.54 ± 0.07 |
| Weight (kg) | |
| Total | 106.28 ± 20.68 |
| Male | 120.50 ± 18.43 |
| Female | 99.10 ± 17.85 |
| BMI (kg/m2) | |
| Total | 41.30 ± 6.31 |
| Male | 41.3 ± 6.72 |
| Female | 41.4 ± 5.52 |
Blood chemistry parameters at the beginning and at the end of the treatment
| Variable | Pre (mean ± ds) | Post (mean ± ds) | Δ change (CI: lower; upper) | |
|---|---|---|---|---|
| Folate | 6.92 ± 5.44 | 12.03 ± 8.64 | 5.11 (3.10; 7.12) | < 0.001* |
| Vit B12 | 355.11 ± 143.46 | 384.15 ± 141.80 | 29.04 (10.31; 47.76) | 0.003 |
| Fe | 85.32 ± 31.16 | 70.8 ± 21.86 | – 14.53 (– 19.13; – 9.92) | < 0.001* |
| Transferrin | 260.19 ± 52.62 | 236.05 ± 45.86 | – 24.14 (– 29.71; – 18.58) | < 0.001* |
| Vit D | 18.88 ± 11.62 | 32.22 ± 14.43 | 13.34 (10.35; 16.34) | < 0.001* |
| ESR | 24.24 ± 18.82 | 24.48 ± 17.92 | 0.236 (– 2.16; 2.63) | 0.846 |
| CRP | 0.69 ± 0.83 | 0.44 ± 0.42 | – 0.25 (– 0.38; – 0.12) | < 0.001* |
| Glycemia | 97.93 ± 22.12 | 87.83 ± 13.84 | – 10.10 (– 12.48; – 7.72) | < 0.001* |
| Hb1Ac | 6.82 ± 1.33 | 6.22 ± 0.88 | – 0.59 (– 0.80; – 0.37) | < 0.001* |
| Insulin | 15.11 ± 8.02 | 12.46 ± 7.30 | – 2.64 (– 3.78; – 1.51) | < 0.001* |
| HOMA | 3.74 ± 2.46 | 2.71 ± 1.80 | – 1.03 (– 1.41; – 0.65) | < 0.001* |
| Uricemia | 6.50 ± 1.49 | 6.42 ± 1.64 | – 0.07 (– 0.29; 0.14) | 0.508 |
| Azotemia | 39.94 ± 15.64 | 40.24 ± 15.9 | 0.30 (– 1.52; 2.12) | 0.744 |
| Creatinine | 0.89 ± 0.25 | 0.94 ± 0.32 | 0.05 (0.03; 0.08) | < 0.001* |
| Na | 139.4 ± 2.09 | 140.03 ± 1.87 | 0.62 (0.25; 0.99) | 0.001 |
| K | 4.41 ± 0.42 | 4.39 ± 0.40 | – 0.02 (– 0.08; 0.04) | 0.457 |
| Cl | 103.58 ± 3.03 | 104.16 ± 2.85 | 0.058 (0.13; 1.03) | 0.012 |
| Ca | 9.360 ± 0.49 | 9.43 ± 0.46 | 0.13 (0.06; 0.20) | < 0.001* |
| Chol Tot | 184.78 ± 40.38 | 160.49 ± 32.86 | – 24.35 (– 28.93; – 19.77) | < 0.001* |
| HDL | 45.48 ± 11.74 | 40.81 ± 8.90 | – 4.67 (– 5.80; – 3.54) | < 0.001* |
| TRG | 141.92 ± 62.40 | 118.65 ± 43.17 | – 23.27 (– 29.35; – 17.19) | < 0.001* |
| LDL | 111.93 ± 37.35 | 99.01 ± 33.48 | – 12.92 (– 17.53; – 8.31) | < 0.001* |
| Apo A | 134.04 ± 25.62 | 119.28 ± 18.77 | – 14.72 (– 17.51; – 12.02) | < 0.001* |
| Apo B | 100.75 ± 25.82 | 87.82 ± 22.03 | – 12.93 (– 15.91; – 9.95) | < 0.001* |
| AST | 19.90 ± 7.15 | 19.55 ± 6.55 | – 0.35 (– 1.26; 0.57) | 0.457 |
| ALT | 25.61 ± 13.35 | 26.01 ± 12.64 | 0.41 (– 1.32; 2.13) | 0.642 |
| gGT | 31.05 ± 21.63 | 22.07 ± 12.89 | – 8.98 (– 11.17; – 6.79) | < 0.001* |
| Prealb | 24.20 ± 5.00 | 22.49 ± 4.55 | – 1.74 (– 2.29; – 1.19) | < 0.001* |
| Phosphatase | 63.29 ± 20.63 | 58.80 ± 18.74 | – 4.49 (– 6.40; – 2.57) | < 0.001* |
| Bilir tot | 0.71 ± 0.29 | 0.58 ± 0.25 | – 0.13 (– 0.16; – 0.10) | < 0.001* |
| Cholinesterase | 10,394.85 ± 2010.58 | 92.77 ± 1924.63 | – 1117.29 (– 1310.45; – 924.12) | < 0.001* |
| Lipase | 23.85 ± 12.57 | 26.42 ± 12.70 | 2.57 (0.90; 4.23) | 0.003 |
| Amylase | 50.30 ± 17.52 | 54.62 ± 19.30 | 4.32 (2.29; 6.34) | < 0.001* |
| Homocysteine | 17.93 ± 5.61 | 16.12 ± 4.87 | – 1.81 (– 2.80; – 0.81) | < 0.001* |
| TSH | 1.97 ± 1.26 | 1.98 ± 1.68 | 0.01 (– 0.23; 0.25) | 0.916 |
| Alfa 2% | 10.38 ± 1.72 | 10.07 ± 1.72 | – 0.30 (– 0.47; – 0.13) | 0.001 |
| Beta % | 11.99 ± 1.50 | 11.50 ± 1.45 | – 0.50 (– 0.63; – 0.37) | < 0.001* |
| Gamma % | 15.28 ± 2.98 | 15.16 ± 2.89 | – 0.12 (– 0.35; 0.11) | 0.294 |
| WBC | 7.01 ± 1.80 | 6.31 ± 1.76 | – 0.70 (– 0.88; – 0.52) | < 0.001* |
| Linf n | 2.345 ± 0.77 | 2.26 ± 0.71 | – 0.08 (– 0.16; 0.01) | 0.030 |
| Linf % | 32.96 ± 7.03 | 36.24 ± 7.65 | 3.32 (2.44; 4.20) | < 0.001* |
| RBC | 4.73 ± 0.50 | 4.65 ± 0.47 | – 0.08 (– 0.12; – 0.04) | < 0.001* |
| HGB | 13.47 ± 1.40 | 13.28 ± 1.30 | – 0.19 (– 0.31; – 0.07) | 0.002 |
| HCT | 41.19 ± 3.93 | 40.65 ± 3.70 | – 0.53 (– 0.93; – 0.14) | 0.008 |
| MCV | 87.89 ± 5.11 | 88.27 ± 4.64 | 0.38 (0.04; 0.072) | 0.030 |
| PLT | 252.02 ± 61.46 | 230.25 ± 56.57 | – 21.77 (– 26.95; – 16.59) | < 0.001* |
95% Confidence Interval of the Difference
*Statistically significant
Body composition parameters at the beginning and end of the treatment
| Variable | Pre (mean ± ds) | Post (mean ± ds) | Δ change (CI: lower; upper) | |
|---|---|---|---|---|
| Arm (cm) | 36.82 ± 4.62 | 35.19 ± 4.06 | – 1.63 (– 1.96; – 1.31) | < 0.001* |
| Calf (cm) | 41.96 ± 4.25 | 40.80 ± 4.06 | – 1.16 (– 1.39; – 0.93) | < 0.001* |
| Total mass (kg) | 104.02 ± 18.61 | 98.35 ± 17.20 | – 5.68 (– 6.24; – 5.11) | < 0.001* |
| FFM (g) | 51,705.83 ± 10,503.63 | 50,469.80 ± 9609.47 | – 1236.03 (– 1595.49; – 876.57) | < 0.001* |
| FM (g) | 49,292.27 ± 10,768.96 | 44,875.43 ± 10,346.06 | – 4416.85 (– 4847.30; – 3986.39) | < 0.001* |
| FM (%) | 48.91 ± 5.79 | 46.96 ± 5.98 | – 1.96 (– 2.26; – 1.65) | < 0.001* |
| FFMI | 20,124.69 ± 2536.29 | 19,537.83 ± 2753.25 | – 586.86 (– 913.19; – 260.52) | < 0.001* |
| FMI | 19,481.78 ± 4607.48 | 17,757.22 + 4465.56 | – 1724.56 (– 1885.48; – 1563.64) | < 0.001* |
| VAT | 2389.23 ± 1028.66 | 2056.48 ± 894.83 | – 332.76 (– 412.79; – 252.72) | < 0.001* |
| SMI | 9.46 ± 1.17 | 9.30 ± 1.19 | – 0.157 (– 0.26; – 0.05) | 0.003 |
95% Confidence Interval of the Difference
FFM, fat free mass, FM fat mass, FFMI fat free mass index, FMI fat mass index, VAT visceral adipose tissue
*Statistically significant
Fig. 1Body composition network analysis
Fig. 2Changes in body composition during the hospitalization period
Variations from discharge up to 1 year of follow-up
| Time | Mean value | Mean difference | Lower | Upper | P value |
|---|---|---|---|---|---|
| Body weight (kg) | |||||
| Discharge | 100.84 | ||||
| T2 | 96.09 | – 4.75 | – 0.79 | – 8.71 | 0.011 |
| T3 | 95.24 | – 5.60 | – 1.64 | – 9.57 | 0.002 |
| T4 | 94.88 | – 5.96 | – 2.00 | – 9.92 | < 0.001* |
| Body mass index (kg/m2) | |||||
| Discharge | 37.56 | ||||
| T2 | 35.80 | – 1.77 | – 0.32 | – 3.21 | 0.009 |
| T3 | 35.48 | – 2.08 | – 0.64 | – 3.53 | 0.001 |
| T4 | 35.40 | – 2.17 | – 0.72 | – 3.61 | < 0.001* |
| Fat mass (g) | |||||
| Discharge | 37,165.33 | ||||
| T2 | 31,896.33 | – 5269.00 | 50.37 | – 10,588.37 | 0.052 |
| T3 | 31,972.67 | – 5192.67 | 126.70 | – 10,512.04 | 0.056 |
| T4 | 31,738.00 | – 5427.33 | – 107.96 | – 10,746.70 | < 0.05* |
| Fat free mass (g) | |||||
| Discharge | 45,072.33 | ||||
| T2 | 44,149.00 | – 923.33 | 2285.30 | – 4131.97 | 1.000 |
| T3 | 43,436.67 | – 1635.67 | 1572.97 | – 4844.30 | 0.579 |
| T4 | 44,174.00 | – 898.33 | 2310.30 | – 4106.97 | 1.000 |
| Visceral adipose tissue (g) | |||||
| Discharge | 1717.33 | ||||
| T2 | 1524.67 | – 192.67 | 598.19 | – 983.52 | 1.000 |
| T3 | 1354.00 | – 363.33 | 427.52 | – 1154.19 | 0.758 |
| T4 | 1319.67 | – 397.67 | 393.19 | – 1188.52 | 0.601 |
*Statistically significant
Fig. 3Changes in body weight, body mass index, fat mass, and VAT for 1-year follow-up